Patents Examined by Marcela M. Cordero Garcia
  • Abaloparatide formulations and methods of testing, storing, modifying, and using same
    Patent number: 10996208
    Abstract: Provided herein are newly discovered methods of analyzing abaloparatide samples for abaloparatide isomers. Additionally, methods of storing and treating with abaloparatide in view of the newly discovered abaloparatide isomers are described.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: May 4, 2021
    Assignee: Radius Health, Inc.
    Inventors: Greg Williams, Naveen Palwai, David Hanley
  • High density peptide polymers
    Patent number: 10980744
    Abstract: Described herein, inter alia, are peptide containing polymers, and methods of making and using the same.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: April 20, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Angela P. Blum, Jacquelin K. Kammeyer, Nathan C. Gianneschi
  • Site-specific chemoenzymatic protein modifications
    Patent number: 10975120
    Abstract: The present invention relates to methods and reagents for use in site-selective modification of proteins having lysine residues with functionalized peptides using a chemoenzymatic microbial transglutaminase-mediated reaction. The functionalized proteins may be used for study or therapeutic uses.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: April 13, 2021
    Assignee: Novartis AG
    Inventors: Aimee Richardson Usera, Zachary Hayes Robinson, Jennifer Stroka Cobb
  • Reagents and methods for analysis of proteins and metabolites targeted by covalent probes
    Patent number: 10969394
    Abstract: The present application relates to mass spectrometry methods for use in identifying proteins or other biomolecules which are bound irreversibly by test compounds.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: April 6, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Jarrod A Marto, Scott B Ficarro, Guillaume Adelmant
  • Methods and uses of alpha 1-antitrypsin for early intervention in pulmonary diseases
    Patent number: 10960062
    Abstract: The present invention disclosed methods for early intervention and prevention of the progression of pulmonary diseases, by administering alpha 1-antitrypsin (AAT) and particularly by administering AAT by inhalation.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: March 30, 2021
    Assignee: KAMADA LTD.
    Inventor: Naveh Tov
  • Analysis of amino acids in body fluid by liquid chromotography-mass spectrometry
    Patent number: 10962550
    Abstract: This disclosure provides methods for quantifying individual amino acids in various bodily fluids obtained from a human patient. Also provided are reference ranges for normal amino acid levels in the various bodily fluids (e.g., blood plasma, urine, cerebrospinal fluid, and saliva) and for various age groups (e.g., neonates, infants, children, and adults).
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: March 30, 2021
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Scott Goldman
  • PEGylated recombinant human growth hormone compounds
    Patent number: 10960053
    Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: March 30, 2021
    Assignee: Ascendis Pharma Endocrinology Division A/S
    Inventors: Harald Rau, Susanne Kindermann, Torben Leßmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogøe
  • Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
    Patent number: 10960054
    Abstract: Disclosed herein includes a drug delivery system comprising at least one peptide and a targeting ligand for bone fracture and/or for bone healing. Some embodiments include a peptide delivery system comprising at least an acidic, basic, hydrophilic, hydrophobic or neutral peptide linked to an acidic peptide or nonpeptidic polyanion for use in targeting the aforementioned attached peptide to a bone fracture surface. In some embodiments, a conjugated peptide expresses an anabolic function that acts through PTH receptor 1, and various formats of targeting ligands guide the drug to raw hydroxyapatite.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: March 30, 2021
    Assignee: Purdue Research Foundation
    Inventors: Philip S. Low, Stewart A. Low, Jeffery Jay Howard Nielsen
  • Linker molecule and use thereof in methods for purifying peptides
    Patent number: 10954266
    Abstract: The present invention relates to a method for the purification of peptides which are produced by solid phase peptide synthesis (SPPS) and corresponding linker molecules for use in said method.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: March 23, 2021
    Assignee: BELYNTIC GMBH
    Inventors: Robert Zitterbart, Oliver Seitz
  • Method for treating lung cancer
    Patent number: 10953069
    Abstract: The present disclosure provides a method for treating lung cancer in a subject in need of such treatment includes administering to the subject a pharmaceutical composition. The pharmaceutical composition includes an effective amount of a betanodavirus B2 protein or a fragment thereof, or a nucleic acid molecule encoding the betanodavirus B2 protein or the fragment and optionally a pharmaceutically acceptable carrier or excipient.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: March 23, 2021
    Assignee: NATIONAL CHENG KUNG UNIVERSITY
    Inventors: Jiann-Ruey Hong, Hsuan-Wen Chiu, Yu-Chin Su
  • Identification and monitoring of cleaved immunoglobulins by molecular mass
    Patent number: 10955420
    Abstract: This document relates to materials and methods for identifying and monitoring immunoglobulin cleavage (e.g., IgG cleavage) in a sample, such as a biological sample, using mass spectrometry techniques.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: March 23, 2021
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: David R. Barnidge, David L. Murray
  • Fusion protein Slit2D2(C386S)-HSA and use thereof in treatment of fibrotic diseases
    Patent number: 10947296
    Abstract: The present invention relates to the field of biomedical technology, in particular to a fusion protein Slit2D2(C386S)-HSA and use thereof in the treatment and/or prevention of fibrotic diseases. In the fusion protein, the amino acid residue is mutated on the basis of the Slit2D2 domain, which improves the stability of the fusion protein compared with the native protein. The above fusion protein is obtained by fusing Slit2D2(C386S) with HSA protein, which prolongs the metabolism time of the drug while improving the stability of the drug. The fusion protein provided by the present invention is more effective than the positive control drug in the prevention and treatment of fibrotic diseases, particularly pulmonary fibrosis, and shows good drug-forming properties.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: March 16, 2021
    Assignee: SUZHOU THINKING POWER BIOTECHNOLOGY CO., LTD.
    Inventors: Huashun Li, Baoyong Ren, Peng Liu
  • GHRH or analogues thereof for use in treatment of hepatic disease
    Patent number: 10946073
    Abstract: The present application relates to novel methods for preventing, slowing the progression of, or treating nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), and/or liver fibrosis, and/or reducing the risks of liver cancer in subjects, such as HIV-infected subjects, using a GHRH molecule, e.g., trans-3-hexenoyl-GHRH(1-44)-NH2, or a pharmaceutically acceptable salt thereof. The subjects may have particular pathological features such as liver fibrosis, a hepatic fat fraction (HFF) of at least about 10%, serum alanine aminotransferase (ALT) levels of at least about 30 U/L, and/or a NAFLD Activity Score (NAS) of at least 4 or 5.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: March 16, 2021
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventor: Steven K. Grinspoon
  • Use of modified vasoactive intestinal peptides in the treatment of hypertension
    Patent number: 10940182
    Abstract: The present invention is based on the discovery that a VIP having a binding preference for VPAC2 can provide long-acting blood pressure control synergistically with concomitant anti-hypertensive therapies. Accordingly, methods and compositions useful for the treatment and/or amelioration of hypertension are provided.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: March 9, 2021
    Assignee: PHASEBIO PHARMACEUTICALS, INC.
    Inventors: Lynne M. Georgopoulos, Susan Arnold
  • Collagen sol for submucosal local injection
    Patent number: 10933171
    Abstract: Object of the present invention is to provide a safe sol for submucosal local injection which gels and creates a mucosal elevation having a high retention rate of mucosal elevation height when locally injected into a digestive submucosa. Provided is a sol for submucosal local injection containing from 0.2 mass % to 1.2 mass % of a collagen, water, a buffer, and from 200 mM to 420 mM sodium chloride.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: March 2, 2021
    Assignees: Tokyo Metropolitan Industrial Technology Research Institute, National University Corporation Gunma University
    Inventors: Toshio Uraoka, Naohisa Yahagi, Shunji Yunoki, Yoshimi Ohyabu, Takefumi Narita
  • Treatment of lower urinary tract epithelium with glucagon like peptide 2
    Patent number: 10925930
    Abstract: The present invention provides a method for treating and/or ameliorating a disorder of the lower urinary tract, comprising administering a composition comprising a glucagon like peptide 2 (GLP-2) receptor agonist to a patient in need thereof in an amount sufficient to treat and/or ameliorate the disorder of the lower urinary tract.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: February 23, 2021
    Assignee: URIGEN N.A.
    Inventors: Christopher P. Meenan, C. Lowell Parsons, Daniel Vickery
  • HSP90 inhibitory peptide conjugate and application thereof in treating tumor
    Patent number: 10918731
    Abstract: The invention discloses a conjugate constructed by conjugating a HSP90 inhibitory peptide to cytotoxic agent via linker and use thereof in the preparing medicine for preventing and/or treating tumor. The mentioned conjugates possess triple anti-tumor effects including targeting delivery, chemotherapy and apoptosis-promotion, which can enhance the anti-tumor efficacy, reduce the dosage, and decrease the toxicity induced by accumulation of chemotherapeutics.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: February 16, 2021
    Assignee: INSTITUTE OF BASIC MEDICAL SCIENCES, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Yanyong Liu, Nan Yang, Pingping Zuo
  • Method to treat hypotension using vasopressin in certain genotypes
    Patent number: 10920278
    Abstract: The present disclosure relates to a method of treating a patient experiencing hypotension, comprising genotyping for a TT, AA, or AT genotype, and administering a therapeutically effective amount of vasopressin based on genotype to maintain a target blood pressure.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: February 16, 2021
    Assignee: PAR PHARMACEUTICAL, INC.
    Inventor: Saji Vijayan
  • Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha
    Patent number: 10913773
    Abstract: Anticachexin C1 inhibits the TNF?-TNF? receptor interaction. In this work, analogs of anticachexin C1 are disclosed. The resulting bicyclic peptides inhibit TNF? TNF?-induced cell death, NF-?B activation, and c-Jun N-terminal kinase (JNK) signaling in cultured mammalian cells. Methods of using the bicyclic peptide anticachexin C1 analogs to treat cancer, inflammatory disorders and immune disorders are also described.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: February 9, 2021
    Assignee: Ohio State Innovation Foundation
    Inventor: Dehua Pei
  • Bioassay for insulin formulations
    Patent number: 10914728
    Abstract: The invention relates to a bioassay of insulin peptide in oral formulations and low affinity insulin peptides in liquid formulations, by for quantifying phosphorylated Akt, thereby avoiding the interference of excipients in potency determination.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: February 9, 2021
    Assignee: Novo Nordisk A/S
    Inventors: Louise Hjerrild Zeuthen, Jan Amstrup, Thomas Aaskov Pedersen